Skip to main content
Contact Us
Subscribe
E-Edition
66°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
TransCode Therapeutics, Inc. - Common Stock
(NQ:
RNAZ
)
7.010
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TransCode Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Looking Into TransCode Therapeutics's Recent Short Interest
January 29, 2024
Via
Benzinga
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024
Highlights TTX-MC138’s Path from Target Discovery to the Clinic
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
February 01, 2024
Shares of Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected thi
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
February 01, 2024
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 31, 2024
Via
Benzinga
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
January 31, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...
Via
Benzinga
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic...
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 12, 2023
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
December 04, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
December 01, 2023
Via
Benzinga
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
November 30, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 15, 2023
Via
Benzinga
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
November 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.